This stock squeezes shorts bad, more pain ahead?

We love second day plays...                                                                                                                                                                                                                                                                                                                                                                                                                 March 28, 2024 This stock squeezes shorts bad, more pain ahead? We love second day plays... *contains sponsored content Good day, 360! Here are our top investing ideas today. These setups look primed! And please join hundreds of us for LIVE TRADING action all day long in the [Market Master’s trading room](. Be the best prepared trader on the Street! AVTX - Up over 250% in the pre-market after acquisition and $185 million in financing secured IBIO - 2nd day play, up over 30% in the pre-market after closing up over 190% yesterday ATLX - Up over 20% in pre after securing $30 million strategic investment and an offtake agreement from Mitsui *sponsored content After selling all day long yesterday, the market kicked into “buying mode” the last 30 minutes of the day to make it look like everything was fine (it wasn’t!). Rumors are that end-of-the-quarter positioning by funds (which ends tomorrow) is leading to roughly $30 BILLION in stock that needs to be sold this week. That is a lot of overhang for even this market to digest… In the meantime, we have our sights locked on a particular sector that is very “high” right now – Cannabis stocks 🚬. This sector has been going BONKERS as the US is hinting at making “natural therapies” legal in all states. TLRY is up over 30%, ACB is up over 50% and CGC takes the crown 👑 this week with a 200% gain (so far!). So today we’ve found a little $.16 stock in this sector ([details on this page]() that hasn’t moved a lot yet (as of time of writing). Honestly, it isn’t even a great company. They just happen to be in the right place at the right time. That could be good enough, considering how frothy this market is right now 🤤. This isn’t the kind of stock we would look to put away in the retirement account, it is purely a short-term idea that screams volatility. If you like fast-moving, low-priced stocks in very hot sectors this may be for you. To see the company name, ticker symbol, and all of the important information on this spicy idea, [click through for our full report](.  *Sponsored content/paid advertisement. This investment involves substantial risk. Please see full disclosure on the [alert page]( for a detailed discussion of risks and atypical results. AVTX - Up over 250% in the pre-market after acquisition and $185 million in financing secured Avalo Therapeutics, Inc. (AVTX) is a clinical stage biotechnology company that focuses on the development of therapies for the treatment of immune dysregulation. In the after-hours yesterday, the [company announced]( that it had Phase 2-ready anti-IL-1β mAb, AVTX-009, through acquisition of AlmataBio, Inc. AVTX also announced a private placement financing of up to $185 Million. Topline results from planned Phase 2 trial in hidradenitis suppurativa expected in 2026. The executed private placement financing of up to $185 million, includes an initial upfront investment of $115.6 million; expected to extend cash runway into 2027. The stock traded up over 250% in the pre-market after the news yesterday. The $21.50 was resistance in the after-hours and in the pre-market and will be an important level to watch. Above it, targets to the upside are $22.50 and then the after-hours high at $24.25. Beyond that, $26, $28, $30 and $32 come into play. Below $21.50, targets to the downside are $20, $19, $18, $17, $16, $12 and $10. Accelerator is off to a great start … It’s just missing YOU! Commit to improve your options selling skills with us in a small-group environment. [Sign up HERE to unlock access to all the training lessons.]( Jason Bond LIVE TODAY 12pm EST. All Lessons Recorded for On-Demand Learning Questions? Contact Davis at davis@ragingbull.com /1-800-585-4488 IBIO - 2nd day play, up over 30% in the pre-market after closing up over 190% yesterday iBio Inc. (IBIO) is a biotechnology company that engages in the development of precision antibodies in the United States. In the after-hours Tuesday, the [company announced]( an AI drug discovery collaboration with AstralBio to rapidly develop novel antibodies for obesity. In addition[ IBIO announced]( a private placement to raise $15 million at $2.85 per share. This will be done with the issuance of 5,287,278 shares of common stock (or pre-funded warrant in lieu thereof) and common warrants to purchase up to 5,287,278 shares of common stock at a purchase price of $2.85 per share. The stock closed up 192.17% yesterday, and traded up over another 30% in pre-market this morning above $4.50. The pre-market high of $4.91 is the first target for bulls. Above it, targets to the upside are $5, $5.24, $5.80, $6, $7, $7.80 and then $8.57. Below $4.91, targets to the downside are $4.50, $4.15, $4, $3.50 , $3, $2.64, $2.50, $2.30 and then $2. ATLX - Up over 20% in pre after securing $30 million strategic investment and an offtake agreement from Mitsui  Atlas Lithium Corporation (ATLX) operates as a mineral exploration and mining company in Brazil. It operates the Minas Gerais lithium project among others. This morning, the [company announced]( it has signed a definitive investment and offtake agreements with Mitsui & Co. Mitsui is purchasing US$ 30,000,000 in common shares of Atlas Lithium at a 10% premium to the 5-day VWAP and at the same time entering into an Offtake Agreement for the future purchase of 15,000 tons of lithium concentrate from Phase 1 and 60,000 tons per year for five years from Phase 2 of Atlas Lithium's soon to be producing Neves Project in Brazil's Lithium Valley. The Strategic Investment provides Atlas Lithium with immediately available funds to continue its rapid development towards revenue generation with the production and sale of high-quality, low cost, environmentally sustainable lithium concentrate. The stock traded up over 20% in the pre-market after the news this morning. $18 was a prior resistance area and will be an important level to watch. Above it, the first target for bulls is the pre-market high at $18.80. Beyond that, $20, $22, $24 and $26 come into play. Below $18, targets to the downside are $17, $16, $15 and then a gap fill at $14.92. Economic Calendar (EST) 👊 By the way, if you are NOT getting our mobile text alerts –  text “RAGE” to 1-(888) 404-5747 to get all of our latest HOT STOCK ideas delivered right to your phone (make sure you put the “1” at the front!). Don’t miss out! Questions or concerns about our products? Email [Support@360wallstreet.io]( © Copyright 2022, RagingBull  DISCLAIMER To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at [( *PAID ADVERTISEMENT. RagingBull has been paid seventeen thousand five hundred dollars by a sponsoring company to produce and distribute this content. See the [alert page]( for full compensation terms. This investment involves substantial risk. Please see full disclosures on the host page, and detailed discussion of risks and atypical results. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers. RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled. WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. [tw]( Update your email preferences or unsubscribe [here]( © 2024 360wallstreet 62 Calef Hwy. #233 Lee, NH 03861, United States of America